ʻO Retatrutide kahi peptide agonist triple-receptor hou i hoʻokumu ʻia mai ka GLP-1-based dual agonist Tirzepatide.. Hoʻoholo ia i ʻekolu kī nā mea hoʻokipa metabolic: ka glucagon receptor (GCGR), ʻO ka mea hoʻokipa polypeptide insulinotropic hilinaʻi glucose (GIPR), a ka glucagon-like peptide-1 receptor (GLP-1R). Hōʻike kēia lāʻau peptide hou i ka mana ikaika i ka mālama ʻana i nā maʻi metabolic pili i ka momona a me ke ʻano 2 ka maʻi diabetes ma muli o kona ʻano ʻokoʻa.
Eia kekahi, Ua hoʻomohala nā kānaka ʻepekema i ka peptide Retatrutide ma kahi scaffold analog GLP-1 i hoʻopaʻa ʻia. 39 nā ʻakika amino. Hoʻokomo ʻia kāna kaʻina i ʻekolu mau amino acid kūlohelohe e hoʻoikaika i ke kū'ē i ka degradation e dipeptidyl peptidase-4 (DPP-4). Eia kekahi, ka hookomo ana o AIB (2-Aminoisobutyric acid) hoʻomaikaʻi nui i ka hana biological a me pharmacokinetics.
Eia hou, ka hoʻopili ʻana o kahi kaulahao diacid momona C20 a lysine koena e hooloihi i kona hapalua ola a hoʻomaikaʻi i kāna ʻano lāʻau lapaʻau. Hui pu, kākoʻo kēia mau hiʻohiʻona kiʻekiʻe i ka dosing subcutaneous i hoʻokahi pule.
Kaʻina
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leo}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Helu CAS
2381089-83-2
ʻĀpana Molekala
C221H342N46O68
Kaumaha Molekala
4731.33 g/mol
Noi'i no na pomaikai Retatrutide:
1. Kāohi i ka ʻai, Hoʻopaneʻe ka hoʻokaʻawale ʻana o ka ʻōpū, a hoʻoikaika i ka insulin
1)Mechanism of Action in Appetite Control:
Ma kahi haʻawina holoholona, kanaka noiʻi hoʻokēʻai kāne ʻiole momona no ka mea 16 hola a mālama iā lākou me nā agonists glucagon receptor lōʻihi, Retatrutide, nā peptides galectin, a me nā mea hoʻohālikelike GLP-1 ʻē aʻe no ka mālama ʻana i ke kaumaha. Ua loiloi ʻia ka haʻawina ʻāʻī ʻai (GE) hoʻopaneʻe, kaumaha kino, a me ka ʻai ʻana.
2) Hoʻopaneʻe ka hoʻokaʻawale ʻana o ka ʻōpū i ka glucose:
ʻIke ʻia, Hoʻopaneʻe ʻo Retatrutide iā GE ma ke ʻano pili i ka glucose. I ke ʻano wae, ka hui e loaa ana 10 ʻO ka nmol/L Retatrutide i hōʻike i ka hōʻemi kiʻekiʻe loa o ke kaumaha o ke kino a me ka emi nui loa o ka ʻai ʻana.
3)Pono Pūnaehana Nervous Central:
Pela no me na mea e ae ʻO GLP-1 agonist receptor, Hana pololei ʻo Retatrutide ka ʻōnaeʻe waena, hoʻonui i ka māʻona a me ka hoʻolohi ʻana i ka hoʻokuʻu ʻana o ka ʻōpū. Ma ka hopena, Kākoʻo ia i ka mālama ʻana i ka momona maikaʻi.
4) Nā hualoaʻa o ke kaumaha kaumaha o ka hoʻāʻo kino:
ʻo kahi laʻana, he pae 2 Ua hōʻike ʻia ka hoʻāʻo ʻana o ke kino i ka pohō nui o ke kaumaha i ka poʻe makua keu a me ka momona: 17.5% ma 24 pule a me 24.4% ma 48 pule pule.
2. ʻAno mālama 2 Diabetes
- ʻO ka Phase 1b ke aʻo ʻana i ka nui o ka piʻi ʻana 2 ʻO nā maʻi maʻi diabetes e loaʻa ana i kēlā me kēia pule o ka Retatrutide a i ʻole nā lāʻau hoʻohaʻahaʻa glucose, me kahi hui hoʻomalu i loaʻa ʻole ka lāʻau lapaʻau.
- Kupaianaha, Loaʻa ka Retatrutide 100% o ka pahu hoemi kaumaha, hoohalikeia me ka wale 2.1% i ka hui hoʻomalu. He ʻokoʻa, ʻaʻohe lāʻau maʻi diabetes ʻē aʻe i hiki 50% ka pono.
- Hōʻike maopopo kēia mau ʻike i ka maikaʻi o Retatrutide i ka mālama ʻana i ke ʻano 2 diabetes. Eia naʻe, ʻO nā hopena ʻaoʻao maʻamau ka gastrointestinal.
- I ka manawa like, i na kanaka makua momona, Ua alakaʻi pū ka mālama ʻana i ka Retatrutide i ke kaumaha nui 48 pule pule.
3. Hoʻolaha i ka hoʻolilo ikehu
- Me he triple agonist, Hoʻoulu ʻo Retatrutide i ka mea hoʻokipa glucagon e like me ka glucagon. Kūkākūkā, hoʻoulu pololei ia i ka thermogenesis a me ka haki ʻana o ka momona.
- He mea nui ia e hoʻomaopopo i ka glucagon receptors aia i loko o ke ake a ʻiʻo adipose. Ma ka ho'ā 'ana i kēia mau mea loa'a, Hoʻonui ka Retatrutide lilo ikehu a me ka hana wela ma ke ake.
- No laila, hoʻonui ia i ka metabolic rate a paipai i ka momona oxidation.
4. Hoʻemi i ka ʻā ʻana a mālama i ka maʻi ʻaʻai momona
1)Pomaikai Anti-Inflammatory:
Hāʻawi ʻo Retatrutide i nā pono anti-inflammatory multi-faceted. ʻo kahi laʻana, Hōʻike nā haʻawina e hoʻomaikaʻi i ka hoʻomanawanui glucose, hoemi i ke kaumaha o ke kino a me ka momona, a hoʻonui i ka lipid profiles.
2)Ka hoʻihoʻi ʻana o Steatohepatitis i nā ʻiole:
Eia hou, hoohuli ia steatohepatitis i ka iole wahine, kākoʻo hoʻoholo o ma'i ate momona ma ka hoemi ana i ka hepatic steatosis. Ma kahi haʻawina, ʻiole i hānai ʻia e nā mea noiʻi i kahi momona momona, ʻai nui-koʻa no 38 Loaʻa nā pule i ka subcutaneous Retatrutide, a ua hookeai ka poe noii ia lakou no 4 hola.
Mahope iho, hōʻike ʻia ka nānā ʻana i ka histological 80% loaʻa i ka steatohepatitis maopopo. ʻO ka mea nui, Hoʻomaikaʻi ʻo Retatrutide i ke ʻano ma muli o ke ʻano, me kekahi mau wahine e hōʻike ana i ka hoʻohuli piha.
3) Nā hopena o ka ʻike moʻolelo:
I kekahi hoʻokolokolo kanaka, lapaʻau nā mea noiʻi 98 nā mea komo me ≥10% ka momona o ka ate. Ma hope 48 nā pule o ka mālama ʻana iā Retatrutide, ua emi iho ka momona o ka ate 51.3% (1 mg), 59% (4 mg), a 86% (12 mg), hoohalikeia me 4.6% i ka hui hoʻomalu.
ʻO ka hope loa, Ua loaʻa i nā maʻi āpau i mālama ʻia i nā pae momona maʻamau.
COA
HPLC
MS
ʻatikala/Literature Citation Notes





